Paradigm Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Paradigm Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$156K	Hold	350	–	–	0.04%	289
2025 Q4	$159K	Hold	350	–	–	0.04%	297
2025 Q3	$137K	Hold	350	–	–	0.03%	294
2025 Q2	$156K	Sell	350 -100	-22%	-$46.1K	0.04%	285
2025 Q1	$218K	Hold	450	–	–	0.06%	252
2024 Q4	$181K	Buy	450 +200	+80%	+$92.7K	0.05%	273
2024 Q3	$116K	Hold	250	–	–	0.03%	313
2024 Q2	$117K	Sell	250 -200	-44%	-$86.8K	0.03%	307
2024 Q1	$188K	Sell	450 -150	-25%	-$63.4K	0.05%	298
2023 Q4	$244K	Hold	600	–	–	0.06%	283
2023 Q3	$209K	Hold	600	–	–	0.06%	290
2023 Q2	$211K	Buy	+600	New	+$202K	0.06%	288
2017 Q2	–	Sell	-200	Closed	-$21.9K	–	657
2017 Q1	$21.9K	Sell	200 -450	-69%	-$39.6K	﹤0.01%	608
2016 Q4	$47.9K	Sell	650 -1,200	-65%	-$97.6K	0.01%	496
2016 Q3	$161K	Buy	1,850 +400	+28%	+$37.8K	0.03%	341
2016 Q2	$125K	Buy	1,450 +249	+21%	+$21.5K	0.02%	386
2016 Q1	$95.5K	Buy	1,201 +51	+4%	+$4.61K	0.02%	471
2015 Q4	$145K	Sell	1,150 -200	-15%	-$24.1K	0.02%	402
2015 Q3	$141K	Sell	1,350 -3,650	-73%	-$469K	0.02%	483
2015 Q2	$617K	Hold	5,000	–	–	0.07%	275
2015 Q1	$590K	Buy	+5,000	New	+$599K	0.07%	284

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Paradigm Asset Management's VRTX Position: Q1 2026 in Review

Paradigm Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 350 shares worth $156K. The position accounts for 0.04% of the portfolio, ranked #289.

Paradigm Asset Management first reported a position in VRTX in Q1 2015 and has held it in 21 quarters since. The position peaked at $617K in Q2 2015. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Paradigm Asset Management held 350 shares of Vertex Pharmaceuticals worth $156K as of Q1 2026.
Paradigm Asset Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.04% of Paradigm Asset Management's portfolio in Q1 2026, its #289 holding.
Paradigm Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 21 quarters since.
Paradigm Asset Management's Vertex Pharmaceuticals position peaked at $617K in Q2 2015.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Paradigm Asset Management's 13F filing for Q1 2026, filed 12 May 2026.